Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2% on Disappointing Earnings

Posted by Stanley Muller on Aug 5th, 2026

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares were down 5.2% during mid-day trading on Monday after the company announced weaker than expected quarterly earnings. The company traded as low as $10.49 and last traded at $10.4980. Approximately 854,494 shares traded hands during trading, a decline of 52% from the average daily volume of 1,776,787 shares. The stock had previously closed at $11.07.

The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02).

Analyst Ratings Changes

ORIC has been the subject of several recent analyst reports. Citigroup reduced their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Oric Pharmaceuticals in a report on Monday, June 8th. The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Friday, May 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Finally, Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $19.27.

Check Out Our Latest Report on Oric Pharmaceuticals

Institutional Trading of Oric Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Federation des caisses Desjardins du Quebec raised its holdings in Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after buying an additional 2,000 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Oric Pharmaceuticals by 184.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after acquiring an additional 2,936 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Oric Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after purchasing an additional 977 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Oric Pharmaceuticals during the third quarter valued at about $60,000. Finally, CANADA LIFE ASSURANCE Co bought a new position in Oric Pharmaceuticals in the third quarter worth about $65,000. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Stock Down 4.6%

The company’s fifty day simple moving average is $9.87 and its 200 day simple moving average is $10.43. The firm has a market capitalization of $1.33 billion, a PE ratio of -8.94 and a beta of 1.02.

Oric Pharmaceuticals Company Profile

(Get Free Report)

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.